Navigation Links
Indiana University Contracts with Virtify for Clinical Trial Disclosure Solutions
Date:8/19/2013

LEXINGTON, Mass., Aug. 19, 2013 /PRNewswire/ -- Virtify, Inc., a leading innovator in content and regulatory information management solutions for the life science industry, today announced Indiana University has signed an enterprise-level contract for its Clinical Trial Registration & Results (CTRR) disclosure software. Indiana University will utilize Virtify's CTRR to fulfill their regulatory obligations by disclosing their clinical trial information to the National Institute of Health's clinicaltrials.gov system. The system is funded and being implemented by the Indiana Clinical and Translational Sciences Institute (CTSI), a statewide partnership among IU, Purdue University and the University of Notre Dame funded by the National Institutes of Health.

(Logo: http://photos.prnewswire.com/prnh/20110131/NE38689LOGO )

"Indiana CTSI will partner with Virtify to help automate the complex clinical trial disclosure processes within the institution in order to fulfill its regulatory requirements. We're pleased to be working with Virtify to develop solutions that will help to reduce the effort it takes to publish the trial information to clinicaltrials.gov," said Richard Kovacs, M.D., associate dean for clinical research at the Indiana University School of Medicine and associate director of the Indiana CTSI.

The old paradigm for managing disclosure throughout the clinical trial process has changed. In the U.S. alone, submissions to www.clinicaltrials.gov are bound by 2,700 unique rules regarding clinical trial registration and 2,500 additional rules for results postings. Many academic and research organizations manage clinical trial disclosure manually, increasing compliance risk and costs.

Virtify's CTRR streamlines and automates the mandatory registration and clinical results disclosure obligations to the National Institute of Health and other registries. It provides a compliance view across all clinical studies, allowing for better reporting, proactive compliance and patient safety. Virtify CTRR is architected for change. Its unique XML Rules Injection™ technology is designed to provide the speed and flexibility needed to meet all global disclosure requirements while minimizing the overhead and complexity of change management. A detailed CTRR fact sheet is available at http://www.virtify.com/default/assets/File/VirtifyCTRR_Global_Clinical_Trial_Disclosure.pdf .           

"Virtify is very pleased to work with Indiana University. Virtify CTRR will not only help improve compliance but will support the disclosure requirements for publishing to medical journals," said Satish Tadikonda, president and CEO of Virtify, Inc. "Virtify CTRR will eliminate duplicate data entry and will enable Indiana University to have a robust and seamless clinical trial disclosure process."

About the Indiana CTSI

The Indiana CTSI is a statewide collaboration of Indiana University, Purdue University and the University of Notre Dame to facilitate the translation of scientific discoveries in the lab into new patient treatments in Indiana and beyond. It was established in 2008 with a Clinical and Translational Science Award totaling more than $30 million from the National Center for Advancing Translational Science at the National Institutes of Health (Grants TR000006, TR000163 and TR000162; PI: A. Shekhar) with additional support from the state, the three member universities, and public and private partners. It is a member of the national network of 60 CTSA-funded organizations across the country. For more information, visit http://www.indianactsi.org.

About Virtify

Virtify is the leading innovator in content and regulatory information management solutions for life sciences. Many of the world's leading organizations rely on Virtify solutions to reduce time-to-market, risk, and costs by managing and automating the complex regulatory compliance and content exchange requirements throughout the product life cycle. Virtify's life science domain expertise has been leveraged by such companies as Genzyme/Sanofi, Novartis, Pfizer/Wyeth, Regeneron, academic research centers and CROs.  Virtify's easy-to-use software suite is the industry's only solution to provide a secure, collaborative, web-based environment for managing regulated content throughout the entire continuum – from pre-clinical through product registration to commercialization. Visit us at http://www.virtify.com.


'/>"/>
SOURCE Virtify, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioStorage Technologies Mike Reffeitt Named "CFO of the Year" by Indianapolis Business Journal
2. BioCrossroads Commemorates Decade of Collaboration, Success for Indiana Life Sciences Sector
3. Positron Accepts Economic Incentives Offer From The City Of Gary, Indiana For $30 Million Towards 70 MeV Cyclotron Project
4. Its Indiana State Fair Season: New BioCrossroads Report Emphasizes Opportunities in Food and Agriculture Innovation
5. Indiana’s Life Sciences Industry Economic Impact Tops $50 billion
6. Indigo Biosystems Among “Best Places to Work” in Indiana
7. StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500
8. Nanounity Announces New Characterization Tools for the 2013 Microscopy & Microanalysis Annual Meeting in Indianapolis, August 4-8
9. Arizona State University engineers aim to improve performance of technology in extreme environments
10. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
11. Causes of Gulf War Illness are complex and vary by deployment area -- Baylor University study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
Breaking Biology News(10 mins):